Connect with us

Biotechnology

4 Biotech Stocks To Watch After Latest M&A Activity

Joe Samuel

Published

on

biotech stocks to buy now

This month the American Society of Clinical Oncology held its annual meeting in Chicago, which brought about more attention to the healthcare sector and biotech stocks. The recent deal between Merck and Tilos Therapeutics has sparked increased enthusiasm within the industry.  The takeover will give Merck control of a pipeline of cancer, fibrosis and autoimmune programs targeting the latent TGFβ complex.

Cancer research remains one of the most critical areas of focus for most investors. This is simply due to the fact that if a company can come up with a truly path-breaking product, then the potential for growth could be significant. With this in mind, here are four biotech stocks to watch on Tuesday.

Small Cap Biotech Stocks Take Center Stage

GT Biopharma (GTBP) has followed suit with a clear focus on immune diseases.  The company’s lead treatment, GTB-1550 is a novel multi-target directed therapy for the treatment of chemotherapy-refractory B-cell malignancies, including Non-Hodgkins Lymphoma and Leukemia.  “GTB-1550 has shown positive results in its two Phase I-II clinical trials in advanced cancer patients who have failed all other therapies, and we are now planning to proceed with a Phase II clinical trial,” explained Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma.

Mr. Cataldo took the reigns on GT Biopharma earlier this year.  He is the founder of the company and one of the key leaders within the industry. His past successes include being the founder and previous CEO of Iovance Biotherapeutics. Anthony Cataldo was able to grow Iovance early on, and the company currently holds a market cap of over $2 billion with a share price above $19 per share.

In addition to the above, the company’s therapy has also shown that it could target HIV infected cells in the University of Minnesota’s preclinical testing. Not only that but in specific tests, data showed that HIV-infected targets that express the HIV envelope on their surface could be eliminated. As the company stated, “The HIV TriKE’s possibility to kill the HIV virus would solve a massive economic burden as well as stop infected patients from spreading the disease.”

Adding to this list of novel biotech stocks to watch, Histogenics Corporation (HSGX) is targeting a pipeline of therapies to treat rare eye diseases.  In April, the company announced a deal with Ocugen Inc. to ultimately take over the company. Ocugen was founded by Pfizer’s Shankar Musunuri and University of Colorado professor Uday Kompella. According to reports, once the merger is complete, Ocugen will try to sell Histogenics’ NeoCart, which is its regenerative treatment designed to treat knee cartilages. HSGX shares saw a jump on Tuesday to highs of nearly $0.23 and have been in an uptrend for the last three trading sessions. 

“Since Ocugen’s founding, we have sought to develop innovative therapies to treat rare and underserved eye diseases through a combination of therapeutic approaches that utilize small molecules, biologics, and gene therapies,” said Shankar Musunuri, Ph.D., M.B.A., Chairman, Chief Executive Officer and Co-Founder of Ocugen.

Big Moves On Penny Stock News

Further to the focus on eye care, NovaBay (NBY) stock has taken on a bright light this week. Since making headlines on Monday, shares of the company have jumped from a close of $0.32 last Friday to highs of $4.78 during Tuesday’s premarket session.  This move of nearly 1,400% comes as the company reported that its Avenova eye-care product is now available without a prescription on Amazon.com through its new direct-to-consumer online channel.

“While prescription Avenova continues to be available through retail pharmacies and direct in-office sales by certain eye care specialists, patients and physicians have asked for greater accessibility to the product,” said NovaBay Chief Executive Justin Hall. “In response, we are launching our new U.S. direct-to-consumer channel, which is a significant step in ensuring easy access at an affordable price.”

A Pop & Drop For Others?

Shares of SINTX Technologies, Inc (SINT) have also begun to rally this week.  The move has come after announcing the renewal of its lease with Portfolio Investments at Centrepointe Business Park for a five-year term. Shares are up by more than 50% since Monday afternoon. 

Dr. Sonny Bal, President & CEO, said, “This is a milestone for SINTX. We have right-sized our operations, and the significant cost savings from the building lease will allow SINTX to focus on scaling up our manufacturing, and invest further in R&D activities.”

As the company explains, “The core strength of SINTX Technologies is the research and development of medical-grade silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride spinal implants in its FDA registered and ISO 13485 certified manufacturing facility for CTL-Amedica, the exclusive retail channel for silicon nitride spinal implants.”

Finally, Midatech Pharma Plc (MTP) saw its stock rise on Tuesday morning.  After closing the previous week near June lows of $1.20, MTP shares have jumped as high as $1.73 this week.  The move comes after the company received a patent titled “Nanoparticle Delivery Compositions.” These will specifically be used to target biologically active agents in the central nervous system.

The company itself focuses on patients with rare and serious cancers. Furthermore, the company’s therapies look to improve bio-delivery and bio-distribution of medicines or agents to areas of the body where they are needed and can exert their actions in an effective, safe, and precise manner.

biotech stock to buy 2019
Pursuant to an agreement between MIDAM VENTURES, LLC and GT Biopharma, Midam was hired for a period from 06/07/2019 – 7/07/2019 to publicly disseminate information about GT Biopharma including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of GT Biopharma in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading
Click to comment

Biotechnology

PharmaCyte Biotech (PMCB) and UTS Creating Advanced Version of Melligen Cells to Treat Diabetes

Joe Samuel

Published

on

biotech stocks to watch

PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced it has entered into a new research agreement with the University of Technology Sydney (UTS) in Australia to create a new version of Melligen cells for the treatment of diabetes with the potential to express higher levels of insulin.

[FULL REPORT] The Future Of Drug Delivery Has Biotech Investors Focusing On One Small Company

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are pleased to have come to an agreement with UTS that allows us to take the Melligen cells to the next level in our development of a ‘bioartificial pancreas’ for the treatment of Type 1 and insulin-dependent Type 2 diabetes. If we are successful, it will bring to fruition the many years of research that have been conducted by Professor Ann Simpson and her colleagues at UTS as well as PharmaCyte in developing these remarkable insulin-producing cells.”

Melligen cells are human liver cells that have been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the body. PharmaCyte has obtained the exclusive worldwide license rights from UTS to use these cells to develop a therapy for Type 1 and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate Melligen cells using the Cell-in-a-Box® technology to protect the Melligen cells from immune system attack in the body and thus function as a “bioartificial pancreas” for purposes of insulin production.

The work undertaken by PharmaCyte, UTS and PharmaCyte’s International Diabetes Consortium over the last two years has resulted in an opportunity to re-engineer the Melligen cells with the aim of increasing their insulin production as well as the bioactivity of the produced insulin. With this new agreement in place, the research will be done in Australia under the leadership of Prof. Ann Simpson, the developer of the original Melligen cell line.

The unique properties that set the Melligen cells apart from all other available insulin-producing cell types, include their robustness, their ability to withstand an attack from cell-toxic molecules that typically lead to the destruction of insulin-producing cells and their suitability for cost-efficient pharmacological-grade large scale production. In contrast to primary beta islet cells of the pancreas, which normally produce insulin and stem-cell-derived insulin producing cells, Melligen cells are a scalable and a highly characterized cell line that can readily be expanded in a bioreactor to generate the amounts of cells needed for cell banking, testing and production.

Professor Simpson commented, “We are extremely pleased that we have come to an agreement with PharmaCyte to continue our work on the Melligen cells and advance them to their full potential. Both UTS and PharmaCyte are investing in this important research because we believe in the significant health impact potential. This takes us a step closer to eliminating the need for diabetics to inject insulin daily and, more importantly, protects them from developing the debilitating complications of the disease such as blindness, neuropathy and possible amputations, kidney failure and cardiovascular problems. We look forward to working with PharmaCyte and its International Diabetes Consortium to improve the Melligen cells and to utilize them with the Cell-in-a-Box®encapsulation technology to create a potential cure for diabetes.”

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is exploring the use of genetically modified liver cells, stem cells and beta islet cells. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

International Diabetes Consortium

PharmaCyte Biotech has established an International Diabetes Consortium (Diabetes Consortium) that consists of world-renowned physicians and scientists from several countries, all of whom share the same goal of developing a treatment for Type 1 and insulin-dependent Type 2 diabetes.

In addition to the Chief Executive Officer, Chief Operating Officer, Chief Scientific Officer and Chief Medical Officer of PharmaCyte, the Diabetes Consortium is made up of well-known physicians and scientists from leading Universities in Munich, Germany, Mannheim, Germany, Vienna, Austria, Barcelona, Spain, Copenhagen, Denmark, and Sydney, Australia. It also involves members from the Karolinska Institute in Stockholm, Sweden, the Vorarlberg Institute for Vascular Investigation and Treatment in Feldkirch, Austria and the biotech company Austrianova in Singapore.

Dr. Eva Maria Brandtner leads the Consortium and is PharmaCyte’s Director of Diabetes Program Development. Dr. Brandtner, who is a consultant for PharmaCyte, previously served as the Chief Scientist with Austrianova. In that role, she conducted preclinical studies with the Melligen cells. Prof. Ann. M Simpson and her colleagues at the University of Technology Sydney developed the Melligen cells. Prof. Simpson is a member of the Consortium.

In addition to key personnel from PharmaCyte, Dr. Brandtner and Prof. Simpson, the Diabetes Consortium includes Prof. Dr. Walter H. Günzburg, the Chief Scientific Officer of PharmaCyte Biotech and the Chief Technical Officer of Austrianova, and Dr. Brian Salmons, the Chief Executive Officer of Austrianova and a member of PharmaCyte’s Medical and Scientific Advisory Board. It also includes research scientists Prof. Dr. Eckhard Wolf and Prof. Dr. Rüdiger Wanke from the Ludwig-Maximillian University (LMU) in Munich, Germany. Both, together with their colleagues at LMU, have developed unique animal models for insulin-dependent diabetes. Other key members of the Diabetes Consortium include Prof. Dr. Hans-Peter Hammes, Professor of Internal Medicine and Endocrinology, Faculty of Clinical Medicine Mannheim of Heidelberg University and Section Leader for Endocrinology and Diabetology, Mannheim, Germany, Prof. Dr. Thomas Stratman of the University of Barcelona in Spain and Prof. Dr. Axel Kornerup Hanson of the University of Copenhagen in Denmark.

About University of Technology Sydney

UTS is a dynamic and innovative university in central Sydney. One of Australia’s leading universities of technology, UTS has a distinct model of learning, strong research performance and a leading reputation for engagement with industry and the professions. Based in the vibrant creative and start-up precinct in Ultimo, it has more than 40,000 students and is rated No.1 ‘young’ university in Australia in both the QS and Times Higher Education rankings.

More information about UTS can be found at www.uts.edu .au.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the United States Securities and Exchange Commission.

More information about PharmaCyte can be found at www.PharmaCyte .com. It can also be obtained by contacting Investor Relations.

Contact:Dr. Gerald W. Crabtree 
Investor Relations: 
PharmaCyte Biotech, Inc. 
Investor Relations Department 
Telephone: 917.595.2856 
Email: Info@PharmaCyte. com

Continue Reading

Biotechnology

3 Biotech Stocks To Watch After Big News This Month

Joe Samuel

Published

on

If there is one sector that has grown immensely strong over the past decade and a half, then it’s biotech. These biotech stocks and underlying companies have come up with highly innovative solutions to a range of diseases. Furthermore, it has been through the use of technology and knowledge of pharmaceuticals, which has added to the innovation.

As a consequence, the sector has grown considerably and a lot of investor capital has flooded into the sector. However, in order to make a return on investment, an investor needs to keep a close eye on the market and then make his investments after he has made a list of the biotech stocks to invest in. On that note, here is a look at 3 biotechnology stocks that proved to be winners recently.

Biotech Stock #1:
PharmaCyte Biotech

PharmaCyte Biotech (PMCB Stock Report) recently announced the appointment of David A. Judd to PharmaCyte’s Medical and Scientific Advisory Board. Mr. Judd has had over 30 years of experience in the research and development of cell culture materials and methods for the culturing various types of human cells. Judd also works at Grand Island Biotechnology Company and is involved in research, process development and cGMP production of biotechnology and cell therapy processes. This could make a perfect fit for him at PharmaCyte.

biotech stocks to buy

If you’re looking at PharmaCyte Biotech at this exact moment, you’re seeing it before the company begins clinical trials and just as it’s preparing to complete its Investigational New Drug Application for the FDA. Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company. At this point, PharmaCyte is focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box.

Here’s why an open IND is key to PharmaCyte (PMCB) realizing a number of benefits that include:

  • Beginning the formal arrangements required to conduct its clinical trial in LAPC.
  • Working towards the major milestone of enrolling the first patient in its clinical trial.
  • Publishing that the technology behind its LAPC treatment has passed the incredibly difficult FDA screening process and met all of the FDA’s regulatory requirements.
  • Building global exposure of PharmaCyte’s Cell-in-a-Box® technology.
  • Paving the way for the development of treatments for multiple diseases including diabetes and a host of solid tumors. 

Biotech Stock #2:
Provention Bio

The next one to look at is Provention Bio Inc (PRVB Stock Report). The biotech stock has been on a hugely impressive rally this year so far. The biotech stock price has surged by as much as 550% in 2019. Why? The big trigger was the results of a National Institute of Health study into the PRV-031 medicine that was published last month.

The study found significant insight in the company’s PRV-031 medicine. If it’s administered over the course of two weeks, the onset of Type 1 diabetes can be delayed by as long as two years. This was found in patients who are at high risk.

PRVB biotech stock price

Additionally, Provention had started a Phase 3 clinical study of the PRV-031 product back in April. That proved to be an important trigger as well. Enrollment for the Phase 2 study of its Crohn’s disease medicine PRV-6527 has also been concluded.

Biotech Stock #3:
ArQule

The other biotech stock to watch had an excellent run in June. The clinical-stage pharmaceutical firm ArQule, Inc. (ARQL Stock Report) stock jumped as much as 53% over the course of last month.

best-biotech-stocks-ARQL-Arqule-stock

This was due to highly promising data from two clinical trials of its product ARQ 531. The trials showed that its medicine had an effect on cancer variants that affect the white blood cells. The biotech stock also managed to raise substantial capital through a private offering. Moreover, the stock is up 280% since the beginning of this year.

biotech stocks to watch
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading

Biotechnology

PharmaCyte Biotech (PMCB) Appoints Cellular Expert to Medical and Scientific Advisory Board

Joe Samuel

Published

on

biotech penny stocks to buy

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has appointed David A. Judd to PharmaCyte’s Medical and Scientific Advisory Board. Mr. Judd has had over 30 years of experience in the research and development of cell culture materials and methods for the culturing various types of human cells. Most importantly, Mr. Judd has worked for many years with the cells that PharmaCyte uses in its treatment of cancer and has a wealth of knowledge regarding their growth properties.


[Free Report] The Future Of Drug Delivery Has Biotech Investors Focusing On One Small Company


PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We feel the appointment of Mr. Judd to our Medical and Scientific Advisory Board comes at a crucial time as we work with our colleagues at Austrianova to conduct the final manufacturing runs to produce successfully the encapsulated cells that are needed for our clinical trial in locally advanced, non-metastatic, pancreatic cancer.”

Mr. Waggoner continued, “Mr. Judd was so intrigued by the possibility that our platform technology may change the way many solid tumors are treated, with little to no chemotherapy side effects, that he volunteered to work with us months ago. He has made significant contributions to our efforts in working with Austrianova to ensure that the cells from our Master Cell Bank grow as they should, both pre and post-encapsulation. During a critical time in realigning certain aspects of the manufacturing process, Mr. Judd accompanied us as an advisor to Austrianova’s cGMP manufacturing facility in Bangkok, Thailand, where the encapsulation of our cells is taking place.

“In a recent video interview, which can be viewed at www.PharmaCyte.com/Media, I spoke to why we selected Mr. Judd to join our team and the contributions he has already made to our Cancer Program. We believe that Mr. Judd’s talents and expertise will be invaluable in the development of cellular therapies for cancer as well as our efforts in the development of cellular therapies for diabetes.”

Mr. Judd is a graduate of the Biotechnology program at Rochester Institute of Technology, the first Biotechnology program in the United States. He has over 30 years of experience in cell culture and biochemistry in research and in a cGMP environment. Also, he has extensive experience in research and development of cell culture medium, both in the upstream and downstream processes.

Mr. Judd is currently employed by the Grand Island Biotechnology Company (Gibco) and is involved in research, process development and cGMP production of biotechnology and cell therapy processes.

Mr. Judd has been employed by Gibco (now owned by ThermoFischer Scientific) for 29 years and is a co-inventor on 5 patents involving cell culture materials.

About PharmaCyte Biotech:

PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is exploring the use of genetically modified liver cells, stem cells and beta islet cells. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


We keep all user information pricate & promise to never spam.*

Privacy Policy

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com